Medindia

DaTscan™ (Ioflupane I 123 Injection) Now Available to Help Physicians Assess Patients with Suspected Parkinsonian Syndromes

PRINCETON, N.J., June 28, 2011 /PRNewswire/ -- GE Healthcare today announced the availability of DaTscan™ (Ioflupane I 123 Injection), in more than 80 hospitals across the US. DaTscan is the first FDA ...
Business Wire

DaTSCAN™ (Ioflupane I 123 Injection) SPECT Imaging Impacts the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome

DUBLIN--(BUSINESS WIRE)--GE Healthcare today presented the results of a randomised controlled study analyzing the effect of DaTSCAN™ (Ioflupane I 123 Injection) SPECT imaging in a group of adult ...
Business Wire

GE Healthcare Presents Parkinsonian Syndromes and Alzheimer’s Disease Research Data and Introduces New Products at Society of Nuclear Medicine and Molecular Imaging Annual ...

VANCOUVER, Canada--(BUSINESS WIRE)--GE Healthcare today announced that results from three company studies utilizing DaTscan™ (Ioflupane I 123 Injection) in Parkinsonian Syndromes or the ...
News Medical

DaTscan allows doctors to differentiate Parkinson's from other movement disorders

Thanks to a new diagnostic imaging technique, physicians now have an objective test to evaluate patients for parkinsonian syndromes, such as Parkinson's disease. Northwestern Memorial Hospital is ...
The American Journal of Managed Care

Effective and Efficient Diagnosis of Parkinsonism: The Role of Dopamine Transporter SPECT Imaging With Ioflupane I-123 Injection (DaTscanâ„¢)

Parkinson’s disease (PD), the second-most common neurodegenerative disease, is characterized by motor and nonmotor symptoms. PD is often misdiagnosed; inappropriate treatment due to misdiagnosis has ...
Medscape

FDA Approves DaTscan for Imaging of Dopamine Transporters

January 17, 2011 — GE Healthcare has announced Food and Drug Administration (FDA) approval of ioflupane iodine-123 injection (DaTscan), a contrast agent for use with single-photon emission computed ...
Monthly Prescribing Reference

DaTscan Approved for Use in Patients With Suspected Lewy Body Dementia

DaTscan is a radioactive diagnostic agent that works by binding reversibly to the human dopamine transporter (DaT) in the brain. The Food and Drug Administration (FDA) has expanded the approval of ...
Science Daily

New imaging test gives physicians better tool to diagnose Parkinson's disease

Physicians now have an objective test to evaluate patients for Parkinsonian syndromes, such as Parkinson's disease. DaTscan™ is the only FDA-approved imaging agent for assessment of movement disorders ...
Yahoo Finance

Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.

ST. LOUIS, April 05, 2022 (GLOBE NEWSWIRE) -- Curium announced today that its generic version of DaTscan (Ioflupane I 123 Injection) was approved on March 30, 2022, by the U.S. Food and Drug ...
Nasdaq

GE Healthcare Announces First Patient Dosed in Phase III Clinical Trial for New Dopamine Transporter Imaging Radiopharmaceutical

First patient dosed in Phase III clinical trial for PET radiopharmaceutical Next stage clinical study also proceeding for SPECT radiopharmaceutical Both imaging agents aim to assist in the evaluation ...
Monthly Prescribing Reference

DaTscan Available to Assess Parkinsonian Syndromes

GE Healthcare announced that DaTscan (Ioflupane I 123 Injection) is available for the detection of dopamine transporters (DaT) in the brains of adult patients with suspected Parkinsonian syndromes.